Related Experiment Video
Updated: May 5, 2026

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation
Published on: November 9, 2013
Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease
L Kristin Newby1, Nancy M Allen LaPointe, Anita Y Chen
1Centers for Education and Research on Therapeutics, Clinical Research Institute, Duke University Medical Center, Durham, NC, USA. newby001@mc.duke.edu
Insights
Long-term use of evidence-based therapies for coronary artery disease (CAD) has improved but remains suboptimal. Consistent use of medications like aspirin and beta-blockers is associated with lower mortality in CAD patients.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Short-term and discharge use of evidence-based therapies for coronary artery disease (CAD) is well-studied.
- Long-term adherence to these crucial medications is less understood.
Purpose of the Study:
- To assess the long-term prevalence and consistency of evidence-based therapy use in CAD patients.
- To identify factors associated with consistent medication use.
- To evaluate the impact of consistent use on patient mortality.
Main Methods:
- Analysis of self-reported medication use (aspirin, beta-blockers, lipid-lowering agents, ACE inhibitors) from 1995-2002 in the Duke Databank for Cardiovascular Disease.
- Logistic regression to identify characteristics of consistent users.
- Cox proportional-hazards models to assess mortality risk associated with consistent use.
Main Results:
- Annual use of all studied medications and their combinations increased from 1995 to 2002.
- Consistent use rates varied: aspirin (71%), beta-blockers (46%), lipid-lowering therapy (44%), ACE inhibitors in heart failure patients (39%).
- Consistent use of most therapies, except ACE inhibitors in non-heart failure patients, was linked to significantly lower adjusted mortality.
Conclusions:
- Evidence-based therapy use for CAD has improved but remains suboptimal.
- Improving long-term adherence to these medications is crucial for better patient outcomes.
- While discharge prescriptions are important, sustained adherence requires further focus and intervention.
Background:
Studies have examined the use of evidence-based therapies for coronary artery disease (CAD) in the short term and at hospital discharge, but few have evaluated long-term use.
Methods And Results:
Using the Duke Databank for Cardiovascular Disease for the years 1995 to 2002, we determined the annual prevalence and consistency of self-reported use of aspirin, beta-blockers, lipid-lowering agents, and their combinations in all CAD patients and of angiotensin-converting enzyme inhibitors (ACEIs) in those with and without heart failure. Logistic-regression models identified characteristics associated with consistent use (reported on > or =2 consecutive follow-up surveys and then through death, withdrawal, or study end), and Cox proportional-hazards models explored the association of consistent use with mortality. Use of all agents and combinations thereof increased yearly. In 2002, 83% reported aspirin use; 61%, beta-blocker use; 63%, lipid-lowering therapy use; 54%, aspirin and beta-blocker use; and 39%, use of all 3. Consistent use was as follows: For aspirin, 71%; beta-blockers, 46%; lipid-lowering therapy, 44%; aspirin and beta-blockers, 36%; and all 3, 21%. Among patients without heart failure, 39% reported ACEI use in 2002; consistent use was 20%. Among heart failure patients, ACEI use was 51% in 2002 and consistent use, 39%. Except for ACEIs among patients without heart failure, consistent use was associated with lower adjusted mortality: Aspirin hazard ratio (HR), 0.58 and 95% confidence interval (CI), 0.54 to 0.62; beta-blockers, HR, 0.63 and 95% CI, 0.59 to 0.67; lipid-lowering therapy, HR, 0.52 and 95% CI, 0.42 to 0.65; all 3, HR, 0.67 and 95% CI, 0.59 to 0.77; aspirin and beta-blockers, HR, 0.61 and 95% CI, 0.57 to 0.65; and ACEIs among heart failure patients, HR, 0.75 and 95% CI, 0.67 to 0.84.
Conclusions:
Use of evidence-based therapies for CAD has improved but remains suboptimal. Although improved discharge prescription of these agents is needed, considerable attention must also be focused on understanding and improving long-term adherence.
More Related Videos
04:24A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
Published on: April 19, 2019
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
Peripheral Artery Disease III: Interprofessional Care